Many diseases are still incurable today. The successful treatment of one disease often creates subsequent medical needs arising from treatment related side effects and reoccurrence or chronicity of diseases.
Wellington is especially interested in financing the development of innovative therapeutic approaches addressing high unmet medical needs. These innovative therapeutics are based on technologies such as novel pathways and targets, proteins and peptides, nucleic acid-based drugs, cell-based therapies and drug delivery. By applying the highest industry standards on product development processes as well as on defining the appropriate target indications and life cycle management strategies early on, young biotech companies and start-ups can generate enormous growth and value. Once a strong preclinical and clinical proof of concept has been demonstrated, companies can benefit from exceptional market opportunities provided by the steadily rising need of big pharma players to add new drug candidates to their pipelines.